Australia: Is The Gene Patent Debate Fuelling Inevitable Change To The Australian Patent System For All Areas Of Technology?


We previously reported that the Australian biotechnology/pharmaceutical patent landscape was in a state a flux. At that time, we were awaiting the recommendations of a Senate Inquiry into the patenting of genes and biological materials. Since then, the recommendations of that Inquiry have been made public. In addition, there have been a number of other significant developments that we believe will inevitably result in significant changes to the patent system in Australia.

Below we discuss the following:

  • The Senate Committee on Community Affairs Inquiry into Gene Patents, November 2010;
  • The Advisory Council on Intellectual Property (ACIP) Report on Patentable Subject Matter, February 2011;
  • The Senate Inquiry into the Patent Amendment (Human Genes and Biological Materials) Bill 2010; and
  • The Intellectual Property Laws Amendment (Raising the Bar) Bill 2011.

Senate Committee on Community Affairs Inquiry into Gene Patents

It is now 12 months since we summarised the issues involved in the Senate Committee on Community Affairs Inquiry into the patentability of genes and other biological material in this journal. On 26 November 2010, the Committee's report was finally released.

The report makes 16 recommendations directed to improving patent quality and the operation of the patent system. Most significantly, the report makes no recommendation that the Patents Act 1990 be amended to expressly prohibit the patenting of genes/biological materials. A copy of the report can be viewed at:

Interestingly, many of the recommendations appear to go beyond the terms of reference of the Inquiry because they relate to all technology areas. Briefly, the recommendations include increasing the threshold requirements for patentability and increasing the support requirements for claims - presumably in an effort to bring Australia's patentability standard into line with Europe and the United States. Recommendations were also made in relation to reinforcing mechanisms and policies by which the Australian Government can, and should, intervene with the rights of patent holders in relation to compulsory licences. Many of the recommendations were made in view of concerns raised that costs associated with the current patent system outweighed its economic and social benefits.

Specifically, the report recommends expanding the prior art base to be considered when assessing whether a claimed invention meets the "inventive step" requirement for patentability. Currently, the inventive step test requires that the disclosure of the prior art directly lead the person skilled in the art to the invention with a reasonable expectation of success (emphasis added). The proposed amendment to this test is whether it is "obvious for the skilled person to try a suggested approach, alternative or method with a reasonable expectation of success" (emphasis added). This proposal appears to introduce some degree of routine experimentation in order to arrive at the claimed invention.

In response to concerns that very broad patent claims were being accepted, the Committee recommended more stringent requirements for "support" for claims by introducing a requirement that a patent claim be enabled across its entire scope and that the description in the patent specification provide sufficient information to allow the skilled addressee to perform the invention without undue experimentation. This seems to mirror the support requirements in the United States and Europe.

One of the terms of reference for the Inquiry was to consider the impact of gene patents on progress in medical research. Although no direct evidence was produced showing that gene patents were inhibiting research, the Committee made a recommendation that a broad research exemption be codified in the Patents Act. The proposed research exemption would apply to acts done for experimental purposes relating to the subject matter of the invention that do not conflict with the normal exploitation of a patent - for example, how an invention works, determining validity and seeking an improvement.

It was clear that not all of the Senators involved with the Inquiry fully supported the recommendation not to exclude genes and biological materials from the Patents Act because two days before the Committee's report was made public, a private member's Bill in support of a broad-reaching amendment to the Patents Act 1990 to prohibit patenting of genes and biological materials was introduced into the Senate by Senator Bill Heffernan, a staunch supporter of banning gene patents. The Bill proposed to amend the Patents Act 1990 by expressly excluding from patentability "biological materials including their components and derivatives, whether isolated or purified or not and however made, which are identical or substantially identical to such materials as they exist in nature" (emphasis added).

The Committee also made a recommendation that a Senate inquiry into the amendment Bill be undertaken (Senate Inquiry into the Patent Amendment (Human Genes and Biological Materials) Bill 2010).

Senate Inquiry into the Patent Amendment (Human Genes and Biological Materials) Bill 2010

Over one hundred submissions were received by this second Senate inquiry, the majority of which criticised the proposed amendment on the basis that the terms "components" "derivatives", and "substantially identical" as used in the amendment lack clarity and would introduce a great deal of ambiguity into what would be considered patentable subject matter. For example, it is not clear as to how much a protein would have to differ from naturally-occurring material to fall outside the scope of the term "substantially identical" and/or "derivative". In response to this criticism, the proponents of gene patent reform altered the proposed amendment to read "biological materials whether isolated or purified or not and however made which are identical to such materials as they exist in nature" (emphasis added); where biological materials", is defined as including DNA, RNA, proteins, cells and fluids including their components; and "identical" means a biological material which is structurally and functionally identical and where any structural change or difference is immaterial to its function. We believe that despite this attempt to make the proposed amendment more palatable, if implemented it would nonetheless introduce substantial ambiguity into the Australian biotechnology patent landscape as well as threaten to exclude from patentability inventions that, on the face of it, seem eminently suited to patentability eg. genetically-altered microbial enzymes for use in cleaning.

Originally, the Committee was due to report its recommendations in June 2011. However, since that time the Committee has been granted two extensions of time in which to report. Some commentators have suggested that the extensions are necessary because the Committee is unable to reach consensus on any recommendations. This appears to be a likely scenario, as it is well known that a number of the Senators involved are uncompromisingly in support of gene patent reform while others do not support the proposed amendment. The new deadline for reporting is 21 September 2011 and the recommendations are eagerly awaited.

Information in relation to the Senate Inquiry, including access to submissions made, can be obtained at the following link:

ACIP Report on Patentable Subject Matter issued 16 February 2011

Following the 2004 Australian Law Reform Commission (ALRC) report on gene patenting and human health in which it was reported that the key concept of patentable subject matter in Australia was ambiguous and obscure, the Minister for Innovation, Industry, Science and Research asked the Advisory Council on Intellectual Property (ACIP) to conduct a review into the appropriateness and adequacy of the manner of manufacture test. The terms of reference for the review asked the ACIP to inquire, report and make recommendations to the Australian Government on patentable subject matter.

The Report of the ACIP was released on 16 February 2011 and included a number of key recommendations including:

(a)   codification of the established principles of patentability by amendment of the Patents Act 1990 to include a statement of the law currently applied by the Courts - namely, that a patentable invention must be an "artificially created state of affairs" in the field of economic endeavour;

(b)   maintenance of the current exclusion from patentability of human beings and biological processes for their generation;

(c)   amendment of the Patents Act 1990 to include a general exclusion from patentability of inventions whose commercial exploitation would be wholly offensive to the Australian public; and

(d)   inclusion in the Patents Act 1990 of a statement of objectives outlining the purpose of the Act so that any test for patentable subject matter must support the objectives of the patent system.

The release of the ACIP Report followed the Report of the Senate Community Affairs Committee Inquiry into the impact of patenting of human genes and biological materials. Significantly, it is noteworthy that the ACIP Report specifically states: "we do not recommend the introduction [into the legislation] of a specific exclusion to prevent the patenting of human genes and genetic products".

The text of the ACIP Report may be viewed at:

Intellectual Property Laws Amendment (Raising the Bar) Bill 2011

In June 2011, Senator Kim Carr, the Minister for Innovation, Industry, Science and Research introduced into the Senate the Intellectual Property Laws Amendment (Raising the Bar) Bill 2011. This has added to the momentum of the push towards change in the Australian patent system – which now seems almost inevitable. This Bill contains no specific recommendations in relation to patentable subject matter, such as proposals to exclude biological inventions. However, like the ACIP report, the Bill includes a number of proposed amendments which aim at increasing the quality of granted patents. Accordingly, biological inventions which are currently eligible for protection may not meet the higher threshold for patentability if the proposed amendments are implemented.

The scope of the proposed reforms is extensive. However, it is relevant to note that there is considerable overlap between the reforms of this Bill with the recommendations of the ACIP report. Most notably, the reforms include proposed amendments directed at increasing the inventive step threshold and increasing the description and support requirements in a patent specification.

The intent of increasing the description and support requirements is to reduce the likelihood that the patentee is granted a monopoly extending beyond the information disclosed in the patent specification. Under the proposed reforms, it will also be necessary for patent attorneys to ensure that all of the claims are fully enabled across their scope.

There is also a proposed amendment requiring that provisional applications "disclose the invention in a manner which is clear enough and complete enough for the invention to be performed by the person skilled in the relevant art".

Some commentators have suggested that if these reforms are introduced, there will be a heavy burden placed on Australian patent attorneys because the amount of time, and therefore the cost, involved in the preparation of specifications will be increased. However, we believe that as the reforms are directed to bringing the Australian patent system into line with Europe and the US, jurisdictions with which Australian patent attorneys are familiar, any necessary changes in drafting practice will not be overly onerous.

A copy of the Bill may be view at:;fileType=application%2Fpdf.


It has been over three years since the gene patent debate was initiated in Australia as a result of a Melbourne-based company, Genetics Technologies, deciding to charge licensing fees to conduct tests for determining susceptibility to breast cancer based on mutations in genes BRCA-1 and BRCA-2. Three years on, it seems that the debate is far from being resolved. Nevertheless, it appears that change to the Australian patent system is inevitable and that these changes will most likely impact all patentable technology areas.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Grant Shoebridge
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.